Corbus Pharmaceuticals said topline results from its Phase 1b CANYON-1 trial of obesity candidate CRB-913 are due in September 2026. The daily oral CB1 inverse

Corbus Pharmaceuticals said topline results from its Phase 1b CANYON-1 trial of obesity candidate CRB-913 are due in September 2026. The daily oral CB1 inverse agonist is a closely watched pipeline asset as companies race to expand obesity treatment options.